Combination Treatment in Newly Diagnosed Patients With Multiple Myeloma
Research conducted by Andrzej J. Jakubowiak, MD, PhD, of the University of Chicago Medicine, and colleagues, tested the efficacy of the monoclonal antibody daratumumab plus the standard of care treatment of carfilzomib, lenalidomide, and dexametahsone (KRd) for patients with newly diagnosed multiple myeloma. The combination therapy produced durable responses, prolonged progression-free survival, and exhibited a beneficial safety profile in these patients. The open-label, phase Ib study findings were presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 8000).
A total of 22 patients with newly diagnosed multiple myeloma regardless of transplantation eligibility were enrolled.
Six patients discontinued therapy. Forty-six percent of patients experienced serious adverse events, with 14% possibly related to treatment with daratumumab. A total of 18 patients experienced a grade 3/4 treatment-emergent adverse event, most commonly lymphopenia and neutropenia. Daratumumab-associated infusion reactions were grade ≤ 2. No grade 5 treatment-emergent adverse events were reported.
The combination therapy yielded a 100% overall response rate (5% complete responses and 86% at least very good partial responses). The 6-month progression-free survival rate was also 100%. The investigators believe the data support further research of this combination therapy as a front-line treatment for this patient population.